Fosfomycin;Fosfomicina

Revista Espanola de Quimioterapia

Volumn 16, Issue 1, 2003, Pages 15-40

  Gobernado, M ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Antibiotics; Fosfomycin; Infections

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; CISPLATIN; CYCLOSPORIN; DALFOPRISTIN PLUS QUINUPRISTIN; FOSFOMYCIN; LOW MOLECULAR WEIGHT HEPARIN; PEPTIDOGLYCAN; POLYMYXIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL CELL WALL; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; DRUG DISTRIBUTION; DRUG EFFECT; HOSPITAL INFECTION; HUMAN; IMMUNOMODULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PHAGOCYTOSIS; REVIEW;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FOSFOMYCIN; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 0037651094     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (298)

1. Hendlin, D., Stapley, E.O., Jackson, M. y cols. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 1969; 166: 122-123.
2. Christensen, B.G., Leanza, J., Beattie, T.R. Phosphonomycin: Structure and synthesis. Science 1969; 166: 123-125.
3. Stapley, E.O., Hendlin, D., Mata, J.M. y cols. Phosphonomycin. I. Discovery and in vitro biological characterization. Antimicrob Agents Chemother 1969; 9: 284-290.
4. Jackson, M., Stapley, E.O. Phosphonomycin. II. Fermentation studies. Antimicrob Agents Chemother 1969; 9: 291-296.
5. Glamkowski, E.J., Gal, G., Purick, R., Davidson, A.J., Sletzinger, M. A new synthesis of the antibiotic phosphonomycin. J Org Chem 1970; 35: 3510-3512.
6. Chaiet, L., Miller, T.W., Goegelman, R.T., Kempf, A.J., Wolf, F.J. Phosphonomycin: Isolation from fermentation sources. J Antibiot Tokyo 1970; 23: 336-347.
7. Hidaka, T., Iwakura, H., Imai, S., Seto, H. Studies on the biosynthesis of fosfomycin. 3. Detection of phosphoenol-pyruvate phosphomutase activity in a fosfomycin high-producing strain of Streptomyces wedmorensis and characterization of its blocked mutant NP-7. J Antibiot Tokyo 1992; 45: 1008-1010.
8. Hidaka, T., Goda, M., Kuzuyama, T., Takei, N., Hidaka, M., Seto, H. Cloning and nucleotide sequence of fosfomycin biosynthetic genes of Streptomyces wedmorensis. Mol Gen Genet 1995; 249: 274-280.
9. Shi, J., Cui, F., Ge, M. The epoxidacion of cis-propenylphosphonic acid to fosfomycin by Penicillium spp. Wei Sheng Wu Xue Bao 2001; 41: 353-356.
10. Schonbrunn, E., Sack, S., Eschenburg, S. y cols. Crystal structure of UDP-N-acetylglucosamine enolpyruvyltransferase, the target of the antibiotic fosfomycin. Structure 1996; 4: 1065-1075.
11. Kahan, F.M., Kahan, S., Cassidy, P.J., Kropp, H. The mechanism of action of fosfomycin (phosphonomycin). Ann NY Acad Sci 1974; 235: 364-386.
12. Schonbrunn, E., Svergun, D.I., Amrhein, N., Koch, M.H. Studies on the conformational changes in the bacterial cell wall biosynthetic enzyme UDP-N-acetylglucosamine enolpyruvyltransferase (MurA). Eur J Biochem 1998; 253: 406-412.
13. Samland, A.K., Amrhein, N., Macheroux, P. Lysine 22 in UDP-N-acetylglucosamine enolpyruvyl transferase from Enterobacter cloacae is crucial for enzymatic activity and the formation of covalent adducts with the substrate phosphoenolpyruvate and the antibiotic fosfomycin. Biochemistry 1999; 38: 13162-13169.
14. Skarzynski, T., Mistry, A., Wonacott, A., Hutchinson, S., Kelly, V.A., Duncan, K. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure 1996; 4: 1465-1474.
15. Gevaudan, M.J., Mallet, M.N., Charrel, J., Dalmas, N., Gulian, C., Gevaudan, P. Cinetique de l'activite antibacterienne de la fosfomycine. Ann Biol Clin Paris 1979; 37: 327-330.
16. Schmid, E.N. Ultrastructure and viability of E. coli treated fosfomycin. Zentralbl Bakteriol Orig A 1979; 245: 48-54.
17. Rodicio, M.R., Manzanal, M.B., Hardisson, C. Protoplast-like structures formation from two species of Enterobacteriaceae by fosfomycin treatment. Arch Microbiol 1978; 118: 219-221.
18. Schmid, E.N. Ultrastructure and viability of K. pneumoniae treated with fosfomycin. Zentralbl Bakterio A 1980; 247: 339-346.
19. Carlone, N.A., Cuffini, A.M., Cattaneo, O. Structural changes induced by subinhibitory concentrations of fosfomycin on Staphylococcus aureus and Bacillus cereus. Microbios 1982; 33: 119-128.
20. Schmid, E.N. Fosfomycin-induced protoplasts and L-forms of Staphylococcus aureus. Chemotherapy 1984; 30: 35-39.
21. Schmid, E.N. Unstable L-form of Proteus mirabilis induced by fosfomycin. Chemotherapy 1985; 31: 286-291.
22. Carlone, N.A., Cuffini, A.M., Cattaneo, O. Fosfomicina. I. Attivita antimicrobica in vivo. G Batteriol Virol Immunol 1977; 70: 100-107.
23. Jung, W.K. Susceptibility of 50 isolates of Clostridium perfringens to cefotaxime, fosfomycin, penicillin G and vancomycin; variable tolerance for vancomycin. Chemotherapy 1983; 29: 99-103.
24. Graninger, W., Leitha, T., Havel, M., Georgopoulos, A. In vitro activity of fosfomycin against methicillin-susceptible and methicillinresistant Staphylococcus aureus. Infection 1984; 12: 293-295.
25. Graninger, W., Leitha, T., Breyer, S., Francesconi, M., Lenz, K., Georgopoulos, A. Methicillin- and gentamicin-resistant Staphylococcus aureus. Susceptibility to fosfomycin, cefamandole, N-formimidoylthienamycin, clindamycin, fusidic acid and vancomycin. Drugs Exp Clin Res 1985; 11: 23-27.
26. MacGowan, A.P., Holt, H.A., Bywater, M.J., Reeves, D.S. In vitro antimicrobial susceptibility of Listeria monocytogenes isolated in the UK and other Listeria species. Eur J Clin Microbiol Infect Dis 1990; 9: 767-770.
27. Inouye, S., Watanabe, T., Tsuruoka, T., Kitasato, I. An increase in the antimicrobial activity in vitro of fosfomycin under anaerobic conditions. J Antimicrob Chemother 1989; 24: 657-666.
28. Hamilton-Miller, J.M. In vitro activity of fosfomycin against 'problem' gram-positive cocci. Microbios 1992; 71: 95-103.
29. Goto, S. Fosfomycin, antimicrobial activity in vitro and in vivo. Chemotherapy 1977; 23 (Suppl. 1): 63-74.
30. Peters, G., Schumacher-Perdreau, F., Pulverer, G. Comparison of activity of fosfomycin, oxacillin and penicillin G against staphylococci and micrococci. Dtsch Med Wochenschr 1980; 105: 1541-1543.
31. Lau, W.Y., Teoh-Chan, C.H., Fan, S.T., Lau, K.F. In vitro and in vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia. J Hyg Lond 1986; 96: 419-423.
32. Grimm, H. In vitro investigations with fosfomycin on Mueller-Hinton agar with and without glucose-6-phosphate. Infection 1979; 7: 256-259.
33. Loulergue, J., Pinon, G., Laudat, P., Audurier, A. La resistance a la fosfomycine chez Staphylococcus saprophyticus et chez les autres especes de staphylocoques coagulase negative. Ann Microbiol Paris 1984; 135A: 239-247.
34. Gayral, J.P., Albertini, M.T., Gallice, E., Olleon, M. Sensibilite a 27 antibiotiques de 858 souches de staphylocoques. Pathol Biol Paris 1986; 34: 368-371.
35. Traub, W.H., Leonhard, B. Comparative susceptibility of clinical group A, B, C, F, and G beta-hemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 1997; 43: 10-20.
36. Soriano, F., Zapardiel, J., Nieto, E. Antimicrobial susceptibilities of Corynebacterium species and other non-spore-forming Gram-positive bacilli to 18 antimicrobial agents. Antimicrob Agents Chemother 1995; 39: 208-214.
37. Martínez-Martínez, L., Suárez, A.I., Winstanley, J., Ortega, M.C., Bernard, K. Phenotypic characteristics of 31 strains of Corynebacterium striatum isolated from clinical samples. J Clin Microbiol 1995; 33: 2458-2461.
38. Laughlin, L.T., Bernat, B.A., Armstrong, R.N. Mechanistic imperative for the evolution of a metalloglutathione transferase of the vicinal oxygen chelate superfamily. Chem Biol Interact 1998; 111-112: 41-50.
39. Farina, C., Boiron, P., Goglio, A., Provost, F. Human nocardiosis in northern Italy from 1982 to 1992. Northern Italy Collaborative Group on Nocardiosis. Scand J Infect Dis 1995; 27: 23-27.
40. Alzugaray, R., González, M.A., Hevia, M.A., Landeras, E., Mendoza, M.C. Yersinia enterocolitica O:3. Antimicrobial resistance patterns, virulence profiles and plasmids. New Microbiol 1995; 18: 215-22.
41. Gómez-Garcés, J.L., Cogollos, R., Alós, J.L. Susceptibilities of fluoroquinolone-resistant strains of Campylobacter jejuni to II oral antimicrobial agents. Antimicrob Agents Chemother 1995; 39: 542-544.
42. Stock, I., Wiedemann, B. An in-vitro study of the antimicrobial susceptibilities of Yersinia enterocolitica and the definition of a database. J Antimicrob Chemother 1999; 43: 37-45.
43. Repáraz, J., Fernández, C. Sensitivity of Vibrio spp. to fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 58-62.
44. Traub, W.H. Clostridium perfringens type A. Comparison of in vitro and in vivo activity of twelve antimicrobial drugs. Chemotherapy 1986; 32: 59-67.
45. Lion, C., Mory, F., Conroy, M.C., Weber, M., Burdin, J.C. Sensibilite atix antibiotiques de Pasteurella multocida et de germes voisins (groupes bacteriens M5 et EF4). Etudes des concentrations minimales inhibitrices par dilution en gelose. Pathol Biol Paris 1986; 34: 1061-1066.
46. Maurin, M., Gasquet, S., Ducco, C., Raoult, D. MICs of 28 antibiotic compounds for 14 Bartonella (formerly Rochalimaea) isolates. Antimicrob Agents Chemother 1995; 39: 2387-2391.
47. Traub, W.H. Comparative in vitro bactericidal activity of 24 antimicrobial drugs against Clostridium perfringens. Chemotherapy 1990; 36: 127-135.
48. Altes Gutiérrez, A., Rodríguez-Noriega, A. In vitro sensitivity of anaerobic bacteria to fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 51-57.
49. García, J.A., Prieto, J., Sáenz, M.C., Sánchez, J.E. Sensitivity of Bacteroidaceae to fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 45-50.
50. Ales, J.M. Evolution of sensitivity to fosfomycin at Jiménez Díaz Foundation. Chemotherapy 1977; 23 (Suppl. 1): 94-98.
51. Andrews, J.M., Baquero, F., Beltrán, J.M. y cols. International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother 1983; 12: 357-361.
52. Hoeprich, P.D., Finn, P.D. Influence of culture media on the antistaphylococcal activity of fosfomycin. Appl Microbiol 1971; 22: 781-783.
53. Drugeon, H., Courtieu, A.L. Il ruolo dei mezzi di coltura sulla sensibilita alla fosfomicina di ceppi di germi Gram-negativi e loro mutanti resistenti. L'influenza del glucosio-6-fosfato. Minerva Med 1978; 69: 4055-4060.
54. Drugeon, H.B., Courtieu, A.L. The role of culture media on the fosfomycin sensitivity of six Serratia strains and their resistant mutants. Chemotherapy 1982; 28: 345-350.
55. Barry, A.L., Fuchs, P.C. In vitro susceptibility testing procedures for fosfomycin tromethamine. Antimicrob Agents Chemother 1991; 35: 1235-1238.
56. Dette, G.A., Knothe, H., Schonenbach, B., Plage, G. Comparative study of fosfomycin activity in Mueller-Hinton media and in tissues. J Antimicrob Chemother 1983; 11: 517-524.
57. Traub, W.H., Spohr, M. Fosfomycin: Interpretation of inhibition zones obtained with the Bauer-Kirby agar disk diffusion susceptibility test. Chemotherapy 1983; 29: 208-212.
58. Salhi, S.L., Gros, P., Salhi, A. Diffusion de la fosfomycine en presence de glucose-6-phosphate a partir de disques pour antibiogramme. Pathol Biol Paris 1985; 33: 509-510.
59. Pfaller, M.A., Barry, A.L., Fuchs, P.C. Evaluation of disk susceptibility testing of fosfomycin tromethamine. Diagn Microbiol Infect Dis 1993; 17: 67-70.
60. Barry, A.L., Pfaller, M.A., Fuchs, P.C. Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine. Eur J Clin Microbiol Infect Dis 1993; 12: 352-356.
61. NCCLS. Performance Standards for Disk Susceptibility Tests. Approved Standard, doc. M2-A8, vol. 23, n° 1. NCCLS, Wayne, Pensylvania, 2003.
62. Neo-Sensitabs. NCCLS method (Kirby-Bauer)-Rapidily growing bacteria. User's Guide 2000; 10.1.0-10.1.5. Rosco, Taastrup, Dianamarca.
63. Fosse, T., David, M.F., Duluc, F., Darmusey, D., Tamalet, C., Toga, B. Etude in vitro de I'association cefamandole-fosfomycine vis-a-vis de souches cliniques de staphylocoques methicilline-resistants. Pathol Biol Paris 1984; 32: 528-531.
64. Quentin, C., Noury, P., Laurent, C., Saivin, S., Bebear, C. Activite in vitro de la fosfomycine associee a la rifampicine, la pefloxacine et l'imipenem sur les staphylocoques (echiquier en milieu liquide). Pathol Biol Paris 1987; 35: 153-157.
65. Quentin, C., Saivin, S., Lafferriere, C., Noury, P., Bebear, C. In vitro activity of fosfomycin combined with rifampin, pefloxacin and imipenem against staphylococci: A study by the time-kill curve method. Drugs Exp Clin Res 1987; 13: 219-224.
66. Borowski, J., Linda, H. Combined action of fosfomycin with beta-lactam and aminoglycoside antibiotics. Chemotherapy 1977; 23 (Suppl. 1): 82-85.
67. Drobnic, L., Quiles, M., Rodríguez, A. A study of the levels of fosfomycin in the cerebrospinal fluid in adult meningitis. Chemotherapy 1977; 23 (Suppl. 1): 180-188.
68. Kikuchi, K., Totsuka, K., Shimizu, K., Ishii, T., Yoshida, T., Orikasa, Y. Effects of combination of benzylpenicillin and fosfomycin on penicillin-resistant Streptococcus pneumoniae. Microb Drug Resist 1995; 1: 185-189.
69. Duez, J.M., Kohli, E., Pechinot, A., Tremeaux, J.C., Kazmierczak, A. Associations entre la fosfomycine et l'oxacilline ou le cefotaxime chez les staphylocoques methicilline-resistants et les enterocoques. Pathol Biol Paris 1983; 31: 515-518.
70. Ferrara, A., Dos Santos, C., Cimbro, M., Gialdroni-Grassi, G. Effect of different combinations of sparflovacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci. Eur J Clin Microbiol Infect Dis 1997; 16: 535-537.
71. Ullmann, U., Lindemann, B. In vitro investigations on the action fosfomycin alone and in combination with other antibiotics on Pseudomonas aeruginosa and Serratia marcescens. Arzneimittelforschung 1980; 30: 1247-1249.
72. Nishida, K., Niidome, K., Hashimoto, M., Otsuki, M., Nishino, T. In vitro synergistic effects of tazobactam/piperacillin with various antibiotics. Jpn J Antibiot 1994; 47: 1348-1362.
73. Portier, H., Kazmierczak, A., Lucht, F., Tremeaux, J.C., Chavanet, P., Duez, J.M. Cefotaxime in combination with other antibiotics for the treatment of severe methicillin-resistant staphylococcal infections. Infection 1985; 13 (Suppl. 1): 123-128.
74. Utsui, Y., Ohya, S., Magaribuchi, T., Tajima, M., Yokota, T. Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1986; 30: 917-922.
75. Takahashi, K., Kanno, H. Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984; 26: 789-791.
76. Okazaki, M., Suzuki, K., Asano, N. y cols. Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother 2002; 8: 37-42.
77. Fosse, T., David, M.F., Duluc, F. Etude in vitro de l'association imipenem-fosfomycine vis-a-vis de souches cliniques de staphylocoques. Pathol Biol Paris 1986; 34: 1055-1059.
78. Schroter, G., Schrettenbrunner, A. Antibacterial effect of N-formimidoyl-thienamycin in combination with amikacin, cefoxitin and fosfomycin on K. pneumoniae and P aeruginosa. Zentralbl Bakteriol Mikrobiol Hyg A 1982; 253: 355-378.
79. Debbia, E., Pesce, A., Schito, G.C. In vitro interactions between teicoplanin and other antibiotics against enterococci and staphylococci. J Hosp Infect 1986; (Suppl. A): 73-77.
80. Debbia, E., Pesce, A., Schito, G.C. In vitro activity of LY146032 alone and in combination with other antibiotics against Gram-positive bacteria. Antimicrob Agents Chemother 1988; 32: 279-281.
81. Rice, L.B., Eliopoulos, G.M., Moellering, R.C. Jr. In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance. Antimicrob Agents Chemother 1989; 33: 470-473.
82. Rice, L.B., Eliopoulos, C.T., Yao, J.D., Eliopoulos, G.M., Moellering, R.C. Jr. In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model. Diagn Microbiol Infect Dis 1992; 15: 173-176.
83. Zuccarelli, M., Simeon de Buochberg, M., Maillols, M., Armynot du Chatelet, A.M., Attisso, M.A. Cinetiques de bactericidie comparees de la ciprofloxacine, de l'ofloxacine et de la pefloxacine seules et en association sur des souches de streptocoques du groupe D. Pathol Biol Paris 1988; 36: 403-409.
84. Niida, M., Yoshida, T., Kohmoto, A., Ogawa, M., Hashimoto, H., Deguchi, K. Studies on the combined effect of fosfomycin with sulbactam/cefoperazone on methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Jpn J Antibiot 1994; 47: 1-10.
85. Gatermann, S., Schulz, E., Marre, R. The microbiological efficacy of the combination of fosfomycin and vancomycin against clinically relevant staphylococci. Infection 1989; 17: 35-37.
86. Miksza Zyllkiewicz, R., Dzierzanowska, D., Linda, H., Borowski, J. Combined action of phosphomycin with streptomycin and gentamicin. Arch Immunol Ther Exp Warsz 1977; 25: 741-747.
87. David, C., Chaste, A., Saison, C., Combremont, A.G. Activite in vitro des associations de la netilmicine et de l'amikacine avec la fosfomycine et la pefloxacine sur trente et une souches de Staphylococcus aureus meticilline-resistantes heterogenes. Pathol Biol Paris 1988; 36: 608-612.
88. Weber, P., Boussougant, Y., Ichou, F., Dutoit, C., Carbon, C. Bactericidal effect of ofloxacin alone and combined with fosfomycin or vancomycin against Staphylococcus aureus in vitro and in sera from volunteers. J Antimicrob Chemother 1987; 20: 839-847.
89. Drugeon, H.B., Caillon, J., Juvin, M.E. In-vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and -resistant Staphylococcus aureus. J Antimicrob Chemother 1994; 34: 899-8907.
90. Fosse, T., Appert, A., Delpech, D., Laffont, C. Activite in vitro de l'acide fusidique en association avec differents antibiotiques vis-a-vis de Staphylococcus epidermidis. Pathol Biol Paris 1988; 36: 621-625.
91. Alvarez, S., Jones, M., Berk, S.L. In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985; 28: 689-690.
92. Tessier, F., Quentin, C. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1997; 16: 159-162.
93. Figueredo, V.M., Neu, H.C. Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis. J Antimicrob Chemother 1988; 22: 41-50.
94. Arca, P., Reguera, G., Hardisson, C. Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J Antimicrob Chemother 1997; 40: 393-399.
95. Mlynarczyk, A., Mlynarczyk, G., Bardowski, J., Osowiecki, H. Chromosomal localization of resistance to fosfomycin and aminocyclitol antibiotics in hospital strains of Staphylococcus aureus. Acta Microbiol Pol 1985; 34: 145-154.
96. Corso, A., Santos, I., Aires de Sousa, M., Rossi, A., de Lencastre, H. Spread of a methicillin-resistant and multiresistant epidemic clone of Staphylococcus aureus in Argentina. Microb Drug Resist 1998; 4: 277-288.
97. Ravdonikas, L.E., Grabovskaya, K.B., Totolian, A.A. Isolation and study of fosfomycin-resistant mutants of group A and B streptococci. Folia Microbiol Praha 1988; 33: 507-512.
98. Venkateswaran, P.S., Wu, H.C. Isolation and characterization of a phosphonomycin-resistant mutant of Escherichia coli K-12. J Bacteriol 1972; 110: 935-944.
99. Hardisson, C., Villar, C.J., Llaneza, J., Mendoza, M.C. Predominance et dispersion des plasmides conferant la resistance a la fosfomycine chez des enterobacteries. Pathol Biol Paris 1984; 32: 755-758.
100. Kurashige, S., Yamaguchi, N., Hiraishi, H., Teshima, C., Mitsuhashi, S. Decrease in the virulence of fosfomycin-resistant Salmonella enteritidis strains. En: Mitsuhashi, S., Hashimoto, J. (Eds.). Microbial Drug Resistance. Univ Park Press, Baltimore 1975; 535-538.
101. Cordaro, J.C., Melton, T., Stratis, J.P. y cols. Fosfomycin resistance: Selection method for internal and extended deletions of the phosphoenolpyruvate:sugar phosphotransferase genes of Salmonella typhimarium. J Bacteriol 1976; 128: 785-793.
102. Gershanovich, V.N., Umiarov, A.M., Burd, G.I., Bol'shakova, T.N., Lycheva, T.A. Shigella flexneri mutation giving rise to the appearance of fosfomycin-resistant avirulent forms with disordered carbohydrate utilization. Zh Mikrobiol Epidemiol Immunobiol 1980; 11: 83-88.
103. Wu, H.C., Venkateswaran, P.S. Fosfomycin-resistant mutant of Escherichia coli. Ann NY Acad Sci 1974; 235: 587-592.
104. Baquero, F., López-Brea, M., Valls, A., Cañedo, T. Fosfomycin and plasmidic resistance. Chemotherapy 1977; 23 (Suppl. 1): 133-140.
105. Llaneza, J., Villar, C.J., Salas, J.A., Suárez, J.E., Mendoza, M.C., Hardisson, C. Plasmid-mediated fosfomycin resistance is due to enzymatic modification of the antibiotic. Antimicrob Agents Chemother 1985; 28: 163-164.
106. Perea, E.J., Daza, R.M., Mendaza, M.P. Genetic localization of the resistance to fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 127-132.
107. Falkinham, J.O., Curtiss, R. Isolation and characterization of conjugation-deficient mutants of Escherichia coli K-12. J Bacteriol 1976; 126: 1194-1206.
108. León, J., García-Lobo, J.M., Ortiz, J.M. Fosfomycin inactivates its target enzyme in Escherichia coli cells carrying a fosfomycin resistance plasmid. Antimicrob Agents Chemother 1983; 24: 276-278.
109. García Lobo, J.M., León, J., Navas, J., Ortiz, J.M. Cloning and expression in minicells of the determinant of resistance to fosfomycin from the transposon Tn2921. Plasmid 1984; 11: 243-247.
110. Zilhao, R., Courvalin, P. Nucleotide sequence of the fosB gene conferring fosfomycin resistance by Staphylococcus epidermidis. FEMS Microbiol Lett 1990; 56: 267-272.
111. Etienne, J., Gerbaud, G., Courvalin, P., Fleurette, J. Plasmid-mediated resistance to fosfomycin in Staphylococcus epidermidis. FEMS Microbiol Lett 1989; 52: 133-137.
112. Etienne, J., Gerbaud, G., Fleurette, J., Courvalin, P. Characterization of staphylococcal plasmids hybridizing with the fosfomycin resistance gene fosB. FEMS Microbiol Lett 1991; 68: 119-122.
113. Navas, J., García-Lobo, J.M, León, J., Ortiz, J.M. Structural and functional analyses of the fosfomycin resistance transposon Tn2921. J Bacteriol 1985; 162: 1061-1067.
114. Navas, J., León, J., Arroyo, M., García-Lobo, J.M. Nucleotide sequence and intracellular location of the product of the fosfomycin resistance gene from transposon Tn2921. Antimicrob Agents Chemother 1990; 34: 2016-2018.
115. Quinn, J.P. Carbon-phosphorus lysate activity. A novel mechanism of bacterial resistance to the phosphonic acid antibiotics? Letters Appl Microbiol 1989; 8: 113-116.
116. Gobernado, M., Santos, M., Diosdado, N., Pérez, F. The evolution of the sensitivity to fosfomycin over the past two years. Chemotherapy 1977; 23 (Suppl. 1): 99-103.
117. Damaso, D., Moreno-López, M., Martínez-Beltrán, J. Evolution of sensitivity to fosfomycin in bacteria isolated in 1973, 1974 and 1975 in the Selvicio de Microbiologia y Epidemiologia of the 'Clinica Puerta de Hierro', Madrid. Chemotherapy 1977; 23 (Suppl. 1): 104-111.
118. Velasco, M.J., Fernández-Crehuet, R., Real, I., Pérez-Navero, J.L., Romanos, A. Infección hospitalaria y resistencia a los antibióticos en una unidad pediátrica de cuidados intensivos. An Esp Pediatr 1988; 29: 122-126.
119. Maple, P.A., Hamilton-Miller, J.M., Brumfitt, W. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet 1989; 1: 537-540.
120. Bert, F., Bruneau, B., Lambert-Zechovsky, N., Branger, C. Etude epidemiologique de la sensibilite aux antibiotiques de Pseudomonas aeruginosa. Pathol Biol Paris 1994; 42: 491-467.
121. Schmid, E.N. Viability and ultrastructure of S. aureus treated with fosfomycin. Zentralbl Bakteriol Mikrobiol Hyg A 1983; 253: 476-488.
122. Mato, R., Santos, I., Venditti, M. y cols. Spread of the multiresistant Iberian clone of methicillin-resistant Staphylococcus aureus (MRSA) to Italy and Scotland. Microb Drug Resist 1998; 4: 107-112.
123. Del Valle, O., Trincado, P., Martín, M.T., Gómez, E., Cano, A., Vindel, A. Prevalencia de Staphylococcus aureus resistentes a meticilina fagotipo 95 en los Hospitales Vall d'Hebron de Barcelona. Enferm Infecc Microbiol Clin 1999; 17: 498-505.
124. Allererger, F., Klare, I. In vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999; 43: 211-217.
125. Chomarat, M., Fredenucci, I., Barbe, G. y cols. Observatoire Rhône-Alpes du pneumocoque en 1999: 35 cas de ménitigites. Pathol Biol (Paris) 2002; 50: 595-598.
126. Gara-Rodríguez, J.A., Trujillano-Martín, I., Baquero, F. y cols. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: A Spanish multicenter study. J Chemother 1997; 9: 394-402.
127. Daza, R., Gutiérrez, J., Piédrola, G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents 2001; 18: 211-215.
128. Fuchs, P.C., Barry, A.L., Brown, S.D. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother 1999; 43: 137-140.
129. Goldstein, F.W. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 2000; 19: 112-117.
130. Kahlmeter, G. An international survey of antimicrobial susceptibility of pathogens from uncomplicated urinary tract infectios: The ECOSENS Project. J Antimicrob Chemother 2003; 51: 69-76.
131. Strachounski, L.S., Shevelev, A.N., Karovina, N.A. y cols. Resistance of E. coli isolated from children with community-acquired urinary tract infections (CA-UTI) in Russia: Results of multicenter study ARMID. 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002; Abstract G-1469.
132. Foltz, E.L., Wallick, H., Rosenblum, C. Pharmacodynamics of phosphonomycin after oral administration in man. Antimicrob Agents Chemother 1969; 9: 322-326.
133. Shimizu, K. Fosfomycin: Absorption and excretion. Chemotherapy 1977; 23 (Suppl. 1): 153-158.
134. Cadorniga, R., Díaz-Fierros, M., Olay, T. Pharmacokinetic study of fosfomycin and its bioavailability. Chemotherapy 1977; 23 (Suppl. 1): 159-174.
135. Kirby, W.M. Pharmacokinetics of fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 141-151
136. Goto, M., Sugiyama, M., Nakajima, S., Yamashina, H. Fosfomycin kinetics after intravenous and oral administration to human volunteers. Antimicrob Agents Chemother 1981; 20: 393-397.
137. Bergan, T. Pharmacokinetic comparison between fosfomycin and otherphosphonic acid derivatives. Chemotherapy 1990; 36 (Suppl. 1): 10-18.
138. Bergogne-Berezin, E., Muller-Serieys, C., Joly-Guillou, M.L., Dronne, N. Trometamol-fosfomycin (Monuril) bioavailability and fooddrug interaction. Eur Urol 1987; 13 (Suppl. 1): 64-68.
139. Segre, G., Bianchi, E., Cataldi, A., Zannini, G. Pharmacokinetic profile of fosfomycin trometamol (Monuril). Eur Urol 1987; 13 (Suppl. 1): 56-63.
140. Bergan, T., Thorsteinsson, S.B., Albini, E. Pharmacokinetic profile of fosfomycin trometamol. Chemotherapy 1993; 39: 297-301.
141. Potel, G., Meignier, M., Baron, D., Reynaud, A., Touze, M.D., Courtieu, A.L. Pharmacokinetics of fosfomycin in normal and burn patients. Effect of probenecid. Drugs Exp Clin Res 1989; 15: 177-184.
142. Ishizawa, T., Sadahiro, S., Hosoi, K., Tamai, I., Terasaki, T., Tsuji, A Mechanisms of intestinal absorption of the antibiotic, fosfomycin, in brush-border membrane vesicles in rabbits and humans. J Pharmacobiodyn 1992; 15: 481-489.
143. Gallego, A., Rodrígues, A., Mata, J.M. Farmacodinamia de la fosfomicina II. Estudios en el hombre. An Inst Farmac Esp 1971; 20: 403-418.
144. Gallego, A., Rodríguez, A., Mata, J.M. Fosfomycin: Pharmacological studies. Future trends in chemotherapy. Drugs of Today 1974; 10 (Suppl.): 161-168.
145. Iwai, N., Nakamura, H., Miyazu, M., Watanabe, Y. A study of the absorption and excretion of fosfomycin sodium in children. Jpn J Antibiot 1991; 44: 345-356.
146. Molina, M.A., Olay, T., Quero, J. Pharmacodynamic data on fosfomycin in underweight infants during the neonatal period. Chemotherapy 1977; 23 (Suppl. 1): 217-222.
147. Guibert, M., Magny, J.F., Poudenx, F., Lebrun, L., Dehan, M. Pharmacocinetique comparee de la fosfomycine au cours de deux modalites d'administration chez le nouveau-ne. Pathol Biol Paris 1987; 35: 750-752.
148. Gobemado, M., García, J., Santos, M., Panadero, J., Diosdado, N. Renal insufficiency and fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 200-203.
149. Fernández-Lastra, C., Marino, E.L., Domínguez-Gil, A., Tabernero, J.M., Grande-Villoria, J. Pharmacokinetics of phosphomycin during haemofiltration. Br J Clin Pharmacol 1984; 17: 477-480.
150. Neuman, M., Fluteau, G. Blood and urinary concentrations of fosfomycin as a function of the renal function value. Chemotherapy 1977; 23 (Suppl. 1): 196-199.
151. Dalet, F., Bade, G., Roda, M. Pharmacokinetics of fosfomycin during hemodialysis. Chemotherapy 1977; 23 (Suppl. 1): 210-216.
152. Revert, L., López, J., Pons, J., Olay, T. Fosfomycin in patients subjected to periodic hemodialysis, Chemotherapy 1977; 23 (Suppl. 1): 204-209.
153. Fernández-Lastra, C., Marino, E.L., Domínguez Gil, A., Tabemero, J.M., González López, A., Yuste, M. The influence of uremia on the accessibility of phosphomycin into interstitial tissue fluid. Eur J Clin Pharmacol 1983; 25: 333-338.
154. Bouchet, J.L., Quentin, C., Albin, H., Vincon, G., Guillon, J., Martin-Dupont, P. Pharmacokinetics of fosfomycin in hemodialyzed patients. Clin Nephrol 1985; 23: 218-221.
155. Bouchet, J.L., Albin, H., Quentin, C. Pharmacokinetics of intravenous and intraperitoneal fosfomycin in continuous ambulatory peritoneal dialysis. Clin Nephrol 1988; 29: 35-40.
156. Bohler, J., Donauer, J., Keller, F. Pharmacokinetic principles during continuous renal replacement therapy: Drugs and dosage. Kidney Int 1999; 56 (Suppl. 72): 24-28.
157. Gallego, A., Marín, B., Rodríguez, A. Farmacodinamia de la fosfomicina I. Estudios en animales. Actas XII Reunión Soc Esp Ciene Fisiol, Santiago de Compostela 1970; 225-228.
158. Sicilia, T., Estévez, E., Rodríguez, A. Fosfomycin penetration into the cerebrospinal fluid of patients with bacterial meningitis. Chemotherapy 1981; 27: 405-413.
159. Stahl, J.P., Croize, J., Bru, J.P. y cols. Diffusion de la fosfomycine dans le liquide cephalo-rachidien au cours des meningites purulentes. Presse Med 1984; 13: 2693-2695.
160. Pfeifer, G., Frenkel, C., Entzian, W. Pharmacokinetic aspects of cerebrospinal fluid penetration of fosfomycin. Int J Clin Pharmacol Res 1985; 5: 171-174.
161. Friedrich, H., Engel, E., Potel, J. Fosfomycin levels in the cerebrospinal fluid of patients with and without meningitis. Immun Infekt 1987; 15: 98-102.
162. Boulard, G., Quentin, C., Scontrini, G., Dautheribes, M,. Pouguet, P., Sabathie, M. Traitement des ventriculites a Staphylococcus epidermidis sur materiel par l'association fosfomycine-aminoside. Evolution des taux ventriculaires de fosfomycine. Pathol Biol Paris 1983; 31: 525-527.
163. Kuhnen, E., Pfeifer, G., Frenkel, C. Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges. Infection 1987; 15: 422-424.
164. Ferreres, L., Paz, M., Román, J., Llopis, A., Gobernado, M. Placental transfer of fosfomycin. Gynecol Invest 1974; 5: 65-72.
165. Ferreres, L., Paz, M., Martin, G., Gobernado, M. New studies on placental transfer of fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 175-179.
166. Koh, B., Izawa, Y., Sugiyama, H., Aoyama, H., Komiya, I. Transfer of fosfomycin into human burn blister fluid and its pharmacokinetic analysis. Jpn J Antibiot 1986; 39: 2863-2868.
167. Legat, F.J., Maier, A., Dittrich, P. y cols. Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome. Antimicrob Agents Chemother 2003; 47: 371-374.
168. Robert, P.Y., Tassy, A. Biodisponibilite des antibiotiques. J Fr Ophtalmol 2000; 23: 510-523.
169. Radda, T.M., Gnad, H.D., Paroussis, P. Fosfomycin levels in human aqueous humor after intravenous administration. Arzneimittelforschung 1985; 35: 1329-1331.
170. Adenis, J.P., Denis, F., Franco, J.L., Mounier, M. Etude de la penetration intraoculaire de la fosfomycine chez l'homme et chez le lapin. J Fr Ophtalmol 1986; 9: 533-537.
171. Forestier, F., Salvanet-Bouccara, A., Leveques, D. y cols. Ocular penetration kinetics of fosfomycin administered as a one-hour infusion. Eur J Ophthalmol 1996; 6: 137-142.
172. Adenis, J.P., Franco, J.L., Mathon, C., Peigne, G., Denis, F. Etude du passage intra-oculaire de la fosfomycine chez l'homme et chez le lapin. Bull Soc Ophtalmol Fr 1987; 87: 1415-1418.
173. Hirt, S.W., Alken, A., Muller, H., Haverich, A., Vomel, W. Perioperative preventive antibiotic treatment with fosfomycin in heart surgery: Serum kinetics in extracorporeal circulation and determination of concentration in heart valve tissue. Z Kardiol 1990; 79: 615-620.
174. Bonora, V., Lozano, C., Santos, M., Paz, M., Báguena, J., Gobernado, M. Fosfomycin in treatment of respiratory bacterial infections. Chemotherapy 1977; 23 (Suppl. 1): 337-341.
175. Llorens, J., Ley, G., Fores, A., Olay, T. Acute infantile pneumonopathies treated with fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 315-323.
176. Farago, E., Kiss, I.J., Nabradi, Z. Serum and lung tissue levels of fosfomycin in humans. Int J Clin Pharmacol Ther Toxicol 1980; 18: 554-558.
177. Berthelot, G., Bergogne-Berezin, E., Kafe, H., Daumal, M., Gillon, J. Etude de la penetration de la fosfomycine dans les secretions bronchiques. Pathol Biol Paris 1983; 31: 519-521.
178. Lastra, C.F., Marino, E.L., Barrueco, M., Gervos, M.S., Gil, A.D. Disposition of phosphomycin in patients with pleural effusion. Antimicrob Agents Chemother 1984; 25: 458-462.
179. Sirot, J., Lopitaux, R., Dumont, C., Rampon, S., Cluzel, R. Diffusion de la fosfomycine dans le tissu osseux chez l'homme. Pathol Biol Paris 1983; 31: 522-524.
180. Meissner, A., Haag, R., Rahmanzadeh, R. Adjuvant fosfomycin medication in chronic osteomyelitis. Infection 1989; 17: 146-151.
181. Hoger, P.H., Seger, R.A., Schaad, U.B., Hitzig, W.H. Chronic granulomatous disease: Uptake and intracellular activity of fosfomycin in granulocytes. Pediatr Res 1985; 19: 38-44.
182. Trautmann, M., Meincke, C., Vogt, K., Ruhnke, M., Lajous-Petter, A.M. Intracellular bactericidal activity of fosfomycin against staphylococci: A comparison with other antibiotics. Infection 1992; 20: 350-354.
183. Hendlin, D., Celozzi, E., Weissberger, B., Foltz, E.L. Effect of fosfomycin on the fecal microflora of man. Chemotherapy 1977; 23 (Suppl. 1): 117-126.
184. Andaker, L., Kling, P.A., Burman, L.G. Antibiotic consumption and faecal bacterial susceptibility in surgical in-patients. Acta Chir Scand 1987; 153: 411-416.
185. Knothe, H., Schafer, V., Sammann, A., Shah, P.M. Influence of fosfomycin on the intestinal and pharyngeal flora of man. Infection 1991; 19: 18-20.
186. Rodríguez, A., Gallego, A., Olay, T., Mata, J.M. Bacteriological evaluation of fosfomycin in clinical studies. Chemotherapy 1977; 23 (Suppl. 1): 247-258.
187. Gismondo, M.R., Romeo, M.A., Lo-Bue, A.M., Chisari, G., Nicoletti, G. Microbiological basis for the use of fosfomycin trometamol as single-dose therapy for simple cystitis. Chemioterapia 1986; 5: 278-282.
188. Arione, R., Fontana, P. Single-dose treatment of lower urinary tract infections with fosfomycin trometamol: Preliminary experiences. Chemioterapia 1987; 6: 295-298.
189. Moroni, M. Monuril in lower uncomplicated urinary tract infections in adults. Eur Urol 1987; 13 (Suppl. 1): 101-104.
190. Naber, K.G., Thyroff-Friesinger, U. Fosfomycin trometamol versus ofloxacin/co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: A multicentre study. Infection 1990; 8 (Suppl. 2): 70-76.
191. Jong, Z., Pontonnier, F., Plante, P. Single dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: Results of a multi-center study in females with uncomplicated lower urinary tract infections. Urol Int 1991; 46: 344-348.
192. Jodal, U. The role of fosfomycin trometamol in the management of urinary tract infections in pediatrics. Infection 1992; 20 (Suppl. 4): 317-320.
193. Reeves, D.S. Treatment of bacteriuria in pregnancy with single dose fosfomycin trometamol: A review. Infection 1992; 20 (Suppl. 4): 313-316.
194. Patel, S.S., Balfour, J.A., Bryson, H.M. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997; 53: 637-656.
195. Stein, G.E. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999; 21: 1864-1872.
196. De Cecco, L., Ragni, N. Urinary tract infections in pregnancy: Monuril single-dose treatment versus traditional therapy. Eur Urol 1987; 13 (Suppl. 1): 108-113.
197. Principi, N., Corda, R., Bassetti, D., Varese, L.A., Peratoner, L. Fosfomycin trometamol versus netilmicin in children's lower urinary tract infections. Chemotherapy 1990; 36 (Suppl. 1): 41-45.
198. Crocchiolo, P. Single-dose fosfomycin trometamol versus multipledose cotrimoxazole in the treatment of lower urinary tract infections in general practice. Multicenter Group of General Practitioners. Chemotherapy 1990; 36 (Suppl. 1): 37-40.
199. Harvard-Davis, R., O'Dowd, T.C., Holmes, W., Small, J., Slack, R.C. A comparative double-blind randomised study of single dose fosfomycin trometamol with trimethoprim in the treatment of urinary tract infections in general practice. Chemotherapy 1990; 36 (Suppl. 1): 34-36.
200. Neu, H.C. Fosfomycin trometamol versus amoxycillin - Single-dose multicenter study of urinary tract infections. Chemotherapy 1990; 36 (Suppl. 1): 19-23.
201. Thoumsin, H., Aghayan, M., Lambotte, R. Single dose fosfomycin trometamol versus multiple dose nitrofurantoin in pregnant women with bacteriuria: Preliminary results. Infection 1990; 18 (Suppl. 2): 94-97.
202. Minassian, M.A., Lewis, D.A., Chattopadhyay, D., Bovill, B., Duckworth, G.J., Williams, J.D. A comparison between single-dose fos- fomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 1998; 10: 39-47.
203. Stein, E. Fosfomycin tromethamine: Single-dose treatment of acute cystitis. Int J Fertil Womens Med 1999; 44: 104-109.
204. Barnett, J.A., Southern, P.M. Jr, Luby, J.P., Sanford, J.P. Efficacy of phosphonomycin in treatment of urinary-tract infections. Antimicrob Agents Chemother 1969; 9: 349-351.
205. Holloway, W.J., Clark, J., Rocco, R. Preliminary clinical trials with phosphonomycin. Antimicrob Agents Chemother 1969; 9: 327-331.
206. Lagunero, R.L., Menéndez, M.L. Infecciones del tracto urinario tratadas con fosfonomicina. Folia Clin Int Barc 1974; 24: 130-148.
207. Gobernado, M., Oleza, J., Santos, M. y cols. Fosfomycin in treatment of chronic urinary tract infection. Chemotherapy 1975; 21: 99-107.
208. Allona, A., Díaz-Cabrera, J.A., Manchado, P. Fosfomycin in chronic urinary infections. Chemotherapy 1977; 23 (Suppl. 1): 267-274.
209. Ureta, A., Magarinos, J.I., Sousa, A.S. Clinical bacteriological evaluation of infantile bacteriuria treated with fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 324-330.
210. Martínez, J., Mendoza, J. Fosfomycin in the bacteriuria of paraplegic patients. Chemotherapy 1977; 23 (Suppl. 1): 275-280.
211. Neuman, M., Fluteau, G. Treatment of urinary infections with fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 259-264.
212. Peters, H.J., Eicher, R. Clinical experience with fosfomycin in urinary tract infections. Munch Med Wochenschr 1981; 123: 748-750.
213. Menéndez, A., Tutor, A., Sousa, A.S. Treatment of respiratory infections with fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 348-357.
214. Bacardi, R., Tornos, J., Moga, I. y cols. Treatment of respiratory infections with fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 343-347.
215. Honorato, J., Pérez-Ortola, R., Masso, R., Reparaz, J.M. Fosfomycin in acute bronchopneumopathies. Chemotherapy 1977; 23 (Suppl. 1): 331-336.
216. Nssen, L,R., Jacobsen, J., Ravn, T.J., Wahlgreen, C., Auning-Hansen, H. Fosfomycin-ampicillin versus gentamicin-ampicillin in the treatment of critically ill patients with pneumonia. Infection 1986; 14: 246-249.
217. Solé Puyo, J.M., Poch Vinals, R. Treatment of chronic suppurated otitis with fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 379-391.
218. Stammberger, H. Fosfomycin - A new antibiotic in rhinootolaryngology. HNO 1983; 31: 436-439.
219. Guggenbichler, J.P. Purulent meningitis in children. II. Treatment and prognosis. Padiatr Padol 1982; 17: 43-65.
220. Stahl, J.P., Croize, J., Baud, A. y cols. Traitement des meningites bacteriennes neurochirurgicales par l'association ceftriaxone-fosfomy- cine. Pathol Biol Paris 1986; 34: 479-482.
221. May, T., Weber, M., Gerard, A. y cols. Traitement des meningites bacteriennes post-traumatiques et post-neurochirurgicales par la ceftriaxone seule ou en association avec la fosfomycine. Pathol Biol Paris 1987; 35: 839-8342.
222. Menardi, G. Infections of the cerebrospinal fluid shunt. Padiatr Padol 1989; 24: 43-48.
223. Berner, R., Heinen, F., Pelz, K., van Velthoven, V., Sauer, M., Korinthenberg, R. Ventricular shunt infection and meningitis due to Bacillus cereus. Neuropediatrics 1997; 28: 333-334.
224. De Bels, D., Korinek, A.M., Bismuth, R., Trystram, D., Coriat, P., Puybasse, L. Empirical treatment of adult postsurgical nosocomial meningitis. Acta Neuchir (Wien) 2002; 144: 989-995.
225. Nord, C.E., Lahnborg, G. Efficacy of metronidazole of and fosfomycin alone and in combination in the treatment of experimentally induced intra-abdominal infections. Scand J Gastroenterol 1984; 90: 15-19.
226. Lindhagen, J., Hadziomerovic, A., Nordlung, S., Zbornik, J. Comparison of systemic prophylaxis with metronidazole-fosfomycin and metronidazole-cephalothin in elective colorectal surgery. Acta Chir Scand 1981; 147: 277-283.
227. Lindhagen, J., Andaker, L., Hojer, H. Comparison of systemic prophylaxis with metronidazole/placebo and metronidazole/fosfomycin in colorectal surgery. A clinical study demonstrating the need for additional anti-aerobic prophylactic cover. Acta Chir Scand 1984; 150: 317-323.
228. Andaker, L., Burman, L.G., Eklund, A. y cols. Fosfomycin/metronidazole compared with doxycycline/metronidazole for the prophylaxis of infection after elective colorectal surgery. A randomised double-blind multicentre trial in 517 patients. Eur J Surg 1992; 158: 181-185.
229. Andaker, L., Hojer, H., Kihlstrom, E., Lindhagen, J. Stratified duration of prophylactic antimicrobial treatment in emergency abdominal surgery. Metronidazole-fosfomycin vs. metronidazole-gentamicin in 381 patients. Acta Chir Scand 1987; 153: 185-192.
230. Olsson-Liljequist, B., Burman, L.G. Introducing fosfomycin for surgical prophylaxis - Emergence of resistance in aerobic faecal gramnegative bacteria of in-patients, but not among strains causing infection after elective colorectal procedures. Scand J Infect Dis 1993; 25: 725-733.
231. Gallardo, A., Sáez, J.M., Enríquez, G. y cols. Surgical suppurating infections and surgical abdominal infections treated with fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 392-398.
232. Nohr, M., Andersen, J.C., Juul-Jensen, K.E. Prophylactic singledose fosfomycin and metronidazole compared with neomycin, bacitracin, metronidazole and ampicillin in elective colorectal operations. Acta Chir Scand 1990; 156: 223-230.
233. Gobernado, M., Pérez de León, A., Santos, M., Mateo, C., Ferreres, L. Fosfomycin in the treatment of gynecological infections. Chemotherapy 1977; 23 (Suppl. 1): 287-292.
234. Ruíz García, A., de la Lastra, A.M., Garzón, J.M., Reig, M., Rodríguez, A. Fosfomycin in puerperal infections and its elimination in lochia. Chemotherapy 1977; 23 (Suppl. 1): 281-286.
235. Michel, C., Viron, B., Delisle, F., Lependoven, C., Mignon, F. Treatment of peritonitis in continuous ambulatory peritoneal dialysis with a combination of fosfomycin and pefloxacin. Pathol Biol Paris 1989; 37: 269-271.
236. Gobernado, M., Santos, M., Paz, M.M. y cols. Fosfomicina en el tratamiento de gastroenterocolitis por E. coli enteropatógenos. Rev Esp Pediatr 1974; 178: 339-446.
237. Baquero, F., Canedo, E., Rodríguez, A., Jaso, E. Enteropathogenic Escherichia coli gastroenteritis in premature infants and children treated with fosfomycin. Arch Dis Child 1975; 50: 367-372.
238. Taylor, C.G., Mascarós, E., Román, J. y cols. Enteropathogenic E. coli gastroenterocolitis in neonates treated with fosfomycin. Chemotherapy 1977; 23 (Suppl. 1): 310-314.
239. Brines, J., Escribano, A., Bori, J.V., Colomer, J. Fosfomycin in infantile acute gastroenteritis. Chemotherapy 1977; 23 (Suppl. 1): 304-309.
240. Nogawa, T., Takeuchi, Y., Watanabe, J. y cols. Clinical trial offosfomycin for Campylobacter enteritis. Jpn J Antibiot 1984; 37: 1620-1624.
241. Yoh, M., Aoki, T., Akao, M., Sakaue, Y., Tsubura, E., Honda, T. Report of questionnaire about enterohemorrhagic Escherichia coli cases caused in the area including Sakai City in 1996. Kansenshogaku Zasshi 1997; 71: 1144-1154.
242. Moriguchi, N., Yagi, K., Yamamoto, T., Yoshioka, K., Kubo, S. The drug sensitivity of enterohemorragic Escherichia coli and antibiotics treatment for hemorrhagic enterocolitis - From an outbreak of enterocolitis in Sakai city. Jpn J Antibiot 1997; 50: 591-596.
243. Ikeda, K., Ida, O., Kimoto, K., Takatorige, T., Nakanishi, N., Tatara, K. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999; 52: 357-362.
244. Tsuboi, I., Ida, H., Yoshikawa, E. y cols. Antibiotic susceptibility of enterohemorrhagic Escherichia coli O157:H7 isolated from an outbreak in Japan in 1996. Antimicrob Agents Chemother 1998; 42: 431-432.
245. Izumikawa, K., Hirakata, Y., Yamaguchi, T. y cols. Escherichia coli 0157 interactions with human intestinal Caco-2 cells and the influence of fosfomycin. J Antimicrob Chemother 1998; 42: 341-347.
246. Sakata, H., Maruyama, S. Result of antibiotic therapy for children with Escherichia coli O26:H11 infection. Kansenshogaku Zasshi 1998; 72: 1-4.
247. Roncoroni, A.J., de Cortigianni, M.R., García-Damiano, M.C. Costo y eficacia del coprocultivo en el diagnóstico etiológico de la diarrea aguda. Bol Oficina Sanit Panam 1989; 107: 381-387.
248. Fukuyama, M., Furuhata, K., Oonaka, K., Hara, T., Sunakawa, K. Antibacterial activity of fosfomycin against the causative bacteria isolated from bacterial enteritis. Jpn J Antibiot 2001; 53: 522-531.
249. Baquero, F., Hortelano, J.G., Navarro, M. y cols. Antibiotherapy of Serratia marcescens septicemia in children. Chemotherapy 1977; 23 (Suppl. 1): 416-422.
250. Baron, D., Touze, M.D., Tasseau, F., Reynaud, A., Derriennic, M., Courtieu, A.L. Comparaison entre fosfomycine-penicilline M et penicilline M-gentamicine. A propos de 35 infections severes a Staphylococcus aureus meticilline-sensibles. Rev Med Interne 1987; 8: 109-114.
251. Gouyon, J.B., Francois, C., Semama, D., Sandre, D., Duez, J.M., Portier, H. Septicemies nosocomiales a staphylocoques epidermidis et aureus chez le nouveau-ne. Ann Pediatr Paris 1990; 37: 21-25.
252. Rodríguez, A., Vicente, M.V., Olay, T. Experimental endocarditis and fosfomycin. Drugs Exp Clin Res 1985; 11: 55-62.
253. Rodríguez, A., Vicente, M.V., Olay, T. Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 1987; 31: 1444-1445.
254. Moreno, S., Ezpeleta, C., Parras, F., Barros, C., Martínez-Beltrán, J., Buzón, L. Cure of a case of Haemophilus aphrophilus endocarditis with a combination of fosfomycin and gentamicin. J Antimicrob Chemother 1986; 18: 771-772.
255. Lebreton, P., Vergnaud, M., Zerr, C., Nigam, M., Kaladji, C., Quesnel, J. Antibiotic prophylaxis using a combination of pefloxacin and fosfomycin in heart surgery with CEC (extracorporeal circulation) in patients allergic to beta-lactams. Cah Anesthesiol 1989; 37: 77-87.
256. Tsuda, S., Kuzuyama, Y., Nakai, H. y cols. Clinical evaluation of imipenem/cilastatin sodium and fosfomycin as second-line combination chemotherapy in severe infections associated with hematologic disorders. Jpn J Antibiot 1993; 46: 171-183.
257. Kitamura, K., Hirai, H., Hosoya, N. y cols. Clinical efficacy offosfomycin in combination with sulbactam/cefoperazone in the treatment of severe infections complicated to blood dyscrasia. Working Group of Kanto Combination Therapy for FOM + SBT/CPZ. Kansenshogaku Zasshi 1998; 72: 761-770.
258. Misawa, S., Tsuda, S., Taniwaki, M. A combined consecutive therapy with fosfomycin and sulbactam/cefoperazone for bacterial infections associated with hematological diseases. Jpn J Antibiot 1995; 48: 514-521.
259. Figueroa, J., Baquero, G., Otal, C., Rodríguez, A. Treatment of typhoid fever with fosfomycin alone and associated to chloramphenicol or ampicillin. Chemotherapy 1977; 23 (Suppl. 1): 365-377.
260. Hernández-Casado, V. Fosfomycin in a traumatological department. Chemotherapy 1977; 23 (Suppl. 1): 403-410.
261. Fernández-Valencia, J.E., Saban, T., Canedo, T., Olay, T. Fosfomycin in osteomyelitis. Chemotherapy 1976; 22: 121-134.
262. Badelon, O., Bingen, E., Sauzeau, C., Lambert-Zechovsky, N., de Ribier, A., Bensahel, H. Choix de l'antibiotherapie de premiere intention dans le traitement des infections osseuses et articulaires de l'enfant. Pathol Biol Paris 1988; 36: 746-749.
263. Klein, U., Pawelzik, M., Opferkuch, W. Influence of beta-lactam antibiotics, fosfomycin and vancomycin on the adherence (hemagglutination) of Escherichia coli-containing different adhesins. Chemotherapy 1985; 31: 138-145.
264. Carlone, N.A., Borsotto, M., Cuffini, A.M., Savoia, D. Effect of fosfomycin trometamol on bacterial adhesion in comparison with other chemotherapeutic agents. Eur Urol 1987; 13 (Suppl. 1): 86-91.
265. Gismondo, M.R., Drago, L., Fassina, C., Garlaschi, M.L., Rosina, M., Lombardi, A. Escherichia coli: Effect of fosfomycin trometamol on some urovirulence factors. J Chemother 1994; 6: 167-172.
266. Kumon, H. Management of biofilm infections in urinary tract. World J Surg 2000; 24: 1193-1196.
267. Moden, K., Ando, E., Iida, M., Kumon, H. Role of fosfomycin in a synergistic combination with ofloxacin against Pseudomonas aeruginosa growing in a biofilm. J Infect Chemother 2002; 8: 216-226.
268. Traub, W.H. Interactions of antimicrobial drugs and combined phagocytic/serum bactericidal activity of defibrinated human blood against Serratia marcescens. III. Beta-lactam antibiotics and fosfomycin. Chemotherapy 1983; 29: 48-57.
269. Pérez-Fernández, P., Herrera, I., Martínez, P., Gómez-Lus, M.L., Prieto, J. Enhancement of the susceptibility of Staphylococcus aureus to phagocytosis after treatment with fosfomycin compared with other antimicrobial agents. Chemotherapy 1995; 41: 45-49.
270. Krause, R., Patruta, S., Daxbock, F., Fladerer, P., Wenisch, C. The effect of fosfomycin on neutrophil function. J Antimicrob Chemother 2001; 47: 141-146.
271. Viano, I., Martinetto, P., Valtz, A., Santiano, M., Barbaro, S. Variability of immune response induced by bacteria treated with subminimal inhibitory concentrations of fosfomycin. Rev Infect Dis 1979; 1: 858-861.
272. De Simone, C., Manganaro, M., Meli, D., Ricca, D., Capozzi, C. Influenza degli antibiotici sulla migrazione leucocitaria. Boll Ist Sieroter Milan 1980; 59: 612-618.
273. Morikawa, K., Oseko, F., Morikawa, S., Sawada, M. Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. Antimicrob Agents Chemother 1993; 37: 2684-2687.
274. Morikawa, K., Oseko, F., Morikawa, S. Immunomodulatory effect of fosfomycin on human B-lymphocyte function. Antimicrob Agents Chemother 1993; 37: 270-257.
275. Morikawa, K., Watabe, H., Araake, M., Morikawa, S. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother 1996; 40: 1366-1370.
276. Matsumoto, T., Tateda, K., Miyazaki, S. y cols. Fosfomycin alters lipopolysaccharide-induced inflammatory cytokine production in mice. Antimicrob Agents Chemother 1999; 43: 697-698.
277. Ishizaka, S., Takeuchi, H., Kimoto, M., Kanda, S., Saito, S. Fosfomycin, an antibiotic, possessed TGF-beta-like immunoregulatory, activities. Int J Immunopharmacol 1998; 20: 765-779.
278. Honda, J., Okubo, Y., Kusaba, M., Kumagai, M., Saruwatari, N., Oizumi, K. Fosfomycin (FOM: I R-2S-epoxypropylphosphonic acid) suppress the production of lL-8 from monocytes via the suppression of neutrophil function. Immunopharmacology 1998; 39: 149-155.
279. Matsumoto, T., Tateda, K., Miyazaki, S. y cols. Immunomodulating effect of fosfomycin on gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 1997; 41: 308-313.
280. Ida, S., Shindoh, Y., Takishima, T. Effect of antibiotics on immediate hypersensitivity reactions in vitro: Suppression of IgE-mediated histamine release from peripheral blood basophils by fosfomycin. Microbiol Immunol 1987; 31: 975-984.
281. Ohtani, I., Ohtsuki, K., Aikawa, T., Anzai, T., Ouchi, J,. Saito, T. Reduction of cisplatin ototoxicity by fosfomycin in animal model. ORL J Otorhinolaryngol Relat Spec 1985; 47: 229-235.
282. Sack, K., Schulz, E., Marre, R., Kreft, B. Fosfomycin protects against tubulotoxicity induced by cis-diaminedichloroplatin and cyclosporin A in the rat. Klin Wochenschr 1987; 1, 65: 525-527.
283. Suzuki, M., Sekiguchi, I., Tamada, T., Tsuru, S. Protective effect of elastase on cis-platinum-induced renal toxicity. Oncology 1991; 48: 474-479.
284. Nakamura, T., Kokuryo, T., Hashimoto, Y., Inui, K.I. Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats. J Pharm Pharmacol 1999; 51: 227-232.
285. Schweitzer, V.G., Dolan, D.F., Abrams, G.E., Davidson, T., Snyder, R. Amelioration of cisplatin-induced ototoxicity by fosfomycin. Laryngoscope 1986; 96: 948-958.
286. Buhrer, C., Atzpodien, J., Oz, S., Henze, G. Fosfomycin does not reduce cytostatic activity of cis-platinum against human osteosarcoma cell lines in vitro. Pediatr Hematol Oncol 1991; 8: 243-249.
287. Olson, J.J., Truelson, J.M., Street, N. y cols. In vitro interaction of cisplatin and fosfomycin on squamous cell carcinoma cultures. Arch Otolaryngol Head Neck Surg 1994; 120: 1253-1257.
288. Jordan, J.A., Schwade, N.D., Truelson, J.M. Fosfomycin does not inhibit the tumoricidal efficacy of cisplatinum. Laryngoscope 1999; 109: 1259-1262.
289. Tandy, J.R., Tandy, R.D., Farris, P., Truelson, J.M. In vivo interaction of cis-platinum and fosfomycin on squamous cell carcinoma. Laryngoscope 2000; 110: 1222-1224.
290. Inouye, S., Niizato, T., Komiya, I., Yuda, Y., Yamada, Y. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. J Pharmacobiodyn 1982; 5: 941-950.
291. Inouye, S., Niizato, T., Takeda, U., Koeda, T. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. J Pharmacobiodyn 1982; 5: 659-669.
292. Ohtani, I., Ohtsuki, K., Aikawa, T., Sato, Y., Anzai, T., Ouchi, J. Protective effect of fosfomycin on cisplatin-induced ototoxicity in rats. Nippon Jibiinkoka Gakkai Kaiho 1984; 87: 833-840.
293. Morin, J.P., Olier, B., Viotte, G., Fillastre, J.P. La fosfomycine peutelle reduire la nephrotoxicite des aminoglycosides? Pathol Biol Paris 1984; 32: 338-342.
294. Ohtani, I., Ohtsuki, K., Aikawa, T. y cols. Protective effect of fosfomycin against aminoglycoside ototoxicity. ORL J Otorhinolaryngol Relat Spec 1985; 47: 42-48.
295. Kreft, B., de Wit, C., Marre, R., Sack, K. Experimental studies on the nephrotoxicity of amphotericin B in rats. J Antimicrob Chemother 1991; 28: 271-281.
296. Nakamura, T., Hashimoto, Y., Kokuryo, T., Inui, K.I. Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Pharm Res 1998; 15: 734-738.
297. Leach, J.L., Wright, C.G., Edwards, L.B., Meyerhoff, W.L. Effect of topical fosfomycin on polymyxin B ototoxicity. Arch Otolaryngol Head Neck Surg 1990; 116: 49-53.
298. Wiedemann, B., Groos, M. Antibacterial activity of fosfomycin trometamol in the urine after simulation of oral doses in a pharmaco-kinetic in vitro model. Eur Urol 1987; 13 (Suppl. 1): 76-79.